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A Non-Stop S-Antigen Gene Mutation Is Associated With Late Onset
Hereditary Retinal Degeneration in Dogs
Abstract
Purpose: To identify the causative mutation of canine progressive retinal atrophy (PRA) segregating as an
adult onset autosomal recessive disorder in the Basenji breed of dog.
Methods: Basenji dogs were ascertained for the PRA phenotype by clinical ophthalmoscopic examination.
Blood samples from six affected cases and three nonaffected controls were collected, and DNA extraction was
used for a genome-wide association study using the canine HD Illumina single nucleotide polymorphism
(SNP) array and PLINK. Positional candidate genes identified within the peak association signal region were
evaluated.
Results: The highest -Log10(P) value of 4.65 was obtained for 12 single nucleotide polymorphisms on three
chromosomes. Homozygosity and linkage disequilibrium analyses favored one chromosome, CFA25, and
screening of the S-antigen (SAG) gene identified a non-stop mutation (c.1216T>C), which would result in
the addition of 25 amino acids (p.*405Rext*25).
Conclusions: Identification of this non-stop SAG mutation in dogs affected with retinal degeneration
establishes this canine disease as orthologous to Oguchi disease and SAG-associated retinitis pigmentosa in
humans, and offers opportunities for genetic therapeutic intervention.
Keywords
progressive retinal atrophy, PRA, mutation, canine, Basenji dogs, s-antigen
Disciplines
Medicine and Health Sciences | Veterinary Medicine
This journal article is available at ScholarlyCommons: https://repository.upenn.edu/vet_papers/77
The gene S-antigen (SAG), also known as arrestin, 
encodes a major soluble rod outer segment protein that exem-
plifies a family of inhibitory proteins that bind tyrosine-phos-
phorylated receptors to block their interaction with specific 
G-proteins to terminate a signal chain. In the retina, arrestin 
binds to activated rhodopsin [1] in rod outer segments, to 
hinder G-protein binding and quench rhodopsin activity [2,3]. 
Mutations in this gene in humans have been associated with 
Oguchi disease, a rare form of autosomal recessive stationary 
night blindness (HGMD). This disease has an unusual but 
characteristic clinical feature, the Mizuo-Nakamura phenom-
enon, in which an unusual golden-yellow discoloration of the 
fundus disappears in the dark-adapted condition and reap-
pears shortly after exposure to light [4]. Patients with Oguchi 
disease usually have night blindness but normal color vision 
and normal cone function [5,6]. Patients exhibiting Oguchi 
disease may later develop retinitis pigmentosa (RP), and in 
other cases, the presence of RP can mask signs of Oguchi 
disease [7-12].
Progressive retinal atrophy (PRA) comprises a group 
of genetically inherited diseases affecting dogs of various 
breeds. Similar to RP in humans, PRA is characterized by 
photoreceptor degeneration causing progressive vision loss, 
culminating in blindness. This is a highly heterogeneous 
group of diseases with more than 12 different causative 
gene mutations already identified in canine populations, 
causing either early or late onset disease, and inherited as 
autosomal dominant, autosomal recessive, or X-linked [for a 
review, see 13]. These canine mutations result in phenotypes 
resembling orthologous human diseases and provide valuable 
large animal models for studying the molecular basis of the 
diseases, and for preclinical trials of potential therapies.
In the Basenji breed, the adult onset of PRA was 
observed, with initial visual loss in dim light (night blind-
ness), which gradually progressed to total blindness. Initial 
visual loss affects the peripheral visual field, but unless the 
dog is used for high visual performance tasks such as agility 
work, the reduction in the visual field (tunnel vision) may not 
be apparent. Despite tunnel vision and night blindness, many 
Basenjis affected with PRA retain adequate forward daylight 
vision for many years, sometimes for their entire natural 
life. This phenotype highly resembles progressive rod-cone 
degeneration (prcd), late onset retinal degeneration affecting 
multiple breeds caused by a point mutation in the PRCD gene 
[14]. A complementary breeding test for dogs affected with 
prcd excluded allelism between these two similar diseases 
[15], and this has been confirmed with PRCD genotyping. 
Complicating this broadly recognizable clinical phenotype 
has been considerable heterogeneity in the disease manifesta-
tion, and uncertainty about whether this clinical heterogeneity 
represented a single protean disorder or an underlying genetic 
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heterogeneity. This problem has been further complicated by 
the extremely small gene pool of Basenjis in the American 
breeding population and the multiple inbreeding loops 
apparent in pedigree analysis.
Linkage disequilibrium (LD) enables genome-wide 
association mapping in populations even when the extended 
pedigree information normally required for linkage analysis 
is either incomplete or missing entirely. Furthermore, the 
development of genome-wide single nucleotide polymorphism 
(SNP) chip arrays has made such mapping widely available 
for humans and several other species, including the dog. In 
humans, mapping has been particularly successful in isolated 
populations [16-20]. In the broader canine population, each 
breed comprises such a genetically isolated population, with 
extensive LD blocks, making the association approach attrac-
tive for mapping traits and disease-causative genes [21-25].
In this study, we report a genome-wide association 
study (GWAS) to map a specific form of PRA in the Basenji 
breed of dog, using six affected dogs and three control dogs. 
Together with homozygosity analysis and consideration of 
the mode of inheritance, we identified a non-stop mutation 
in SAG that cosegregated with the disease phenotype and 
caused the disease. This creates an opportunity to study 
the molecular basis of SAG-associated retinal diseases, and 
a model for evaluating potential therapeutic approaches for 
Oguchi disease and SAG-associated RP in humans.
METHODS
Samples: All procedures involving animals were conducted 
following the guidelines of the Institute for Laboratory 
Animal Research (Guide for the Care and Use of Labora-
tory Animals), the U.S. Public Health Service (Public Health 
Service Policy on Humane Care and Use of Laboratory 
Animals), and the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals 
in Ophthalmic and Vision Research. Blood samples were 
collected by cephalic or jugular venepuncture into vacutainer 
tubes containing ethylenediaminetetraacetic acid (EDTA) 
anticoagulant from 80 purebred Basenji dogs: 19 diagnosed 
clinically as affected with PRA, six diagnosed clinically as 
tentatively affected with PRA, 18 nonaffected controls beyond 
the assumed age of risk (at least 6 years of age), and 37 with 
no assigned phenotype either because they were younger than 
the assumed age of risk or due to lack of information. Blood 
was stored at 4 °C or -20 °C until DNA extraction. DNA was 
similarly extracted from blood samples of 110 purebred dogs 
from 22 different breeds not known to segregate this disease 
(Appendix 1).
Phenotypic evaluation of study dogs: Ascertainment of 
disease phenotype was based entirely on indirect ophthal-
moscopic examination by board-certified veterinary ophthal-
mologists. In the minority of cases, the ophthalmoscopic 
diagnosis was confirmed with clinical electroretinography. 
The cases studied in the present report include only dogs 
examined and diagnosed by either or both of two of the 
authors (GMA, GDA), although in several cases the initial 
diagnostic examination was previously performed by other 
veterinarians.
Genome-wide association study: Of the 19 purebred Basenji 
dogs diagnosed clinically as affected with PRA, six were 
selected as cases for association analysis, based on confi-
dence in the disease ascertainment (dogs affected with stage 
II PRA), consistency of the disease phenotype among the 
selected dogs, pedigree information supporting autosomal 
recessive inheritance identical by descent (IBD), and choosing 
the least closely related set of dogs affected with PRA avail-
able (four dogs had no parents or grandparents in common).
Among 43 Basenji dogs not expressing PRA symptoms, 
three dogs not affected with PRA were selected for the control 
group based on having no parents or grandparents in common 
with each other, being clinically diagnosed as nonaffected 
with PRA at an age beyond the apparent age of risk for onset 
of the disease (ages 11.7, 7.5, and 6 years old), being free of 
other ocular abnormalities that might obscure or confuse the 
presence of PRA, and being close relatives of the affected 
dogs chosen as cases. The unaffected dog at age 6, although 
borderline for the age of onset, was a sibling of an affected 
dog, and was chosen to accomplish the fourth criterion.
Samples were genotyped using the Illumina Canine SNP 
chip (HD Canine SNP Chip), which comprises 173,662 SNP 
loci, following the manufacturer’s standard protocol. Geno-
types were called using GenomeStudio (Illumina, San Diego, 
CA). Genotype calls were converted into Plink-format files, 
and association was tested using the association command 
without pedigree or sex information (PLINK) [26]. The 
genotype calls for chromosomes 4, 13, and 25 were retrieved 
from the files and assembled into haplotypes to identify 
homozygous blocks.
Homozygous block analysis: Homozygous block analysis 
was performed on affected dogs only (n=6) using Plink, 
under the following criteria: sliding window criteria: 1,000 
Kb, 150 SNPs, five missing calls, one heterozygous call, 
0.05 threshold; homozygous segment criteria: length 1,000 
Kb, 150 SNPs, 50 density (Kb/SNP). The output was then 
filtered for those chromosomes where all six cases showed 
a minimum of one homozygous segment anywhere in the 
chromosome. The segments then were aligned within each 
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chromosome, to identify those where all six dogs shared the 
same homozygous block. For all such regions, genotype calls 
were retrieved to determine whether all homozygous blocks 
were homozygous for the same haplotype. If so, then the 
“affected haplotype” was compared to haplotypes observed 
in the control group.
Candidate gene analysis: Within a homozygous block on 
chromosome 25 (CFA25), two genes were considered candi-
dates: S-antigen, arrestin (SAG), which has been associated 
with Oguchi disease, as well as retinitis pigmentosa [27-29], 
and potassium inwardly-rectifying channel, subfamily 
J, member 13 (KCNJ13), which has been associated with 
snowflake vitreoretinal degeneration and Leber congenital 
amaurosis [30,31].
SAG screening was performed on five dogs: one Basenji 
affected with PRA and its nonaffected litter-mate, two nonaf-
fected Basenji dogs, and one normal Boxer dog. Eighteen 
primer pairs were used to amplify the 16 coding exons, 
as well as two intronic regions rich with single nucleotide 
polymorphisms (Appendix 2: A). KCNJ13 gene screening 
was conducted on six dogs: two affected Basenji dogs, three 
unaffected Basenjis, and one normal Boxer dog. Nine primer 
pairs were designed to amplify the three exons of the gene 
(Appendix 2B). PCR products of both genes were sequenced, 
and sequences aligned using Sequencher 4.2.2 Software 
(Gene Codes, Ann Arbor, MI).
S-antigen mutation screening in the Basenji population and 
in other breeds: The identified SAG non-stop mutation was 
genotyped on the complete set of Basenji dogs available 
(N=80) with PCR using primer pairs flanking the mutation 
(Appendix 2A, pair number 18), followed by sequencing. An 
allele-specific extension test was then designed to screen 
110 dogs from 22 breeds (Appendix 1). One primer pair, 
containing a forward primer specific to the wild-type allele, 
amplifies a 259 bp fragment, and a separate primer pair, 
containing a forward primer specific to the mutant allele, 
amplifies a 531 bp product (Appendix 2C). Both forward 
primers contain a mismatch in the 3′ penultimate base.
RESULTS
Clinical evaluation: PRA as a clinical disease in the Basenji 
was, in broad terms, typical adult onset canine retinal degen-
eration. The first ophthalmoscopically observed evidence 
of disease was irregular hypo- and hyperreflectivity of the 
tapetal fundus. This phenomenon, taken as evidence of 
retinal thinning, is referred to as stage I or early stage PRA. 
Basenjis affected with PRA typically exhibited evidence of 
stage I PRA at about 5 years of age. These dogs when reex-
amined ophthalmoscopically at a later age typically showed 
progression of disease by thinning (attenuation) of the retinal 
vasculature, which usually became ophthalmoscopically 
evident by 6 or 7 years of age. This phenomenon, taken as 
evidence of reduced blood flow through the retinal vascula-
ture, is referred to as stage II or mid-stage PRA. In all of these 
respects, Basenjis affected by PRA closely resemble dogs of 
other breeds affected by the prcd form of PRA.
Clinical diagnosis of PRA in the Basenji was complicated 
by several factors, however. These included a common preva-
lence of conus in dogs affected with PRA and nonaffected 
dogs. Conus refers to a roughly triangular region immedi-
ately superior to the optic nerve head in which the tapetum 
is yellow (and may be hyperreflective) compared to the 
surrounding green tapetal region. This phenomenon is seen, 
though less frequently, in normal dogs of other breeds, but 
also is seen in dogs of other breeds as one of the earliest signs 
of retinal thinning. In the fundus of Basenjis affected with 
PRA, this area of conus is sometimes observed to expand and 
become hyperreflective. Second, the optic nerve head is typi-
cally less myelinated and thus less extensive over the fundus 
than is typical of other breeds of dog. Also seen repeatedly 
in Basenjis affected with PRA and nonaffected Basenjis was 
a strange mottled golden-yellow-brown discoloration of the 
tapetal fundus that obscured the tapetal reflection in a patchy 
manner, and gave the fundus a beaten bronze appearance. 
This fundus change, termed bronzing, could either mask 
the earliest signs of retinal degeneration in some Basenjis 
affected with PRA or produce a mottled variation in tapetal 
reflectivity that to some extent mimicked the earliest signs of 
retinal degeneration in Basenjis that eventually proved to be 
not affected with PRA.
Finally, the fundus appearance in Basenjis affected with 
PRA was often patchy, or non-uniform, within a given eye, 
between the two eyes of a given affected dog, and among 
affected dogs. To some extent, this fundus appearance is 
observed in other forms of canine PRA, but was particularly 
evident in the eyes of Basenjis affected with PRA (Figure 1).
Pedigree analysis and selection of cases and controls: The 
breeding population of Basenjis in the United States of 
America (i.e., Basenjis registered with the American Kennel 
Club) descends from a small number of founders, and has 
a complicated pedigree structure with multiple inbreeding 
loops and overlapping generations. In combination with 
the late age of onset, and the heterogeneous clinical nature 
of the disease, this made pedigree analysis more uncer-
tain than usual in terms of establishing the likely mode of 
inheritance. A subset of six affected dogs were thus chosen 
for the genome-wide association study with criteria (see the 
Methods) intended to maximize the likelihood that all six 
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dogs were affected with a single autosomal recessive disease 
inherited from a common ancestor, and thus identical by 
descent (Figure 2).
Genome-wide association study results: Nine dogs were 
genotyped for the 173,662 SNPs on the HD Canine Illumina 
array: six affected with PRA and three controls. Genotype 
calls were converted to Plink files, and association analysis 
was run comparing the six affected dogs to the three controls, 
without considering pedigree relationship or gender. The 
highest -Log10(P) value of 4.65 was obtained for 12 SNPs: 
one SNP on CFA4, seven on CFA13, and four SNPs on 
CFA25 (Table 1; Figure 3). All affected dogs were homozy-
gous for the same allele of the single CFA4 SNP (at position 
14,140,022), and all non-affected dogs were homozygous 
for the complementary allele. Haplotype analysis in a 2 Mb 
interval surrounding this SNP (13,146,696–15,141,399), iden-
tified a 1.05Mb block of homozygosity in the control group 
(13,378,063–14,426,721), and heterozygosity in five out of the 
six affected dogs (data not shown). Since the cross-breeding 
test with dogs affected with PRCD suggested that the disease 
is recessive [15], this locus was not further investigated.
Affected dogs were all homozygous for one allele at all 
seven SNPs on CFA13, and nonaffected dogs were homo-
zygous for the complementary allele. Haplotype analysis of 
the approximately 7 Mb interval (37,566,130–44,870,466) 
spanning these seven SNPs in affected dogs showed five 
homozygous blocks containing one or two of these seven 
significant SNPs, with distances ranging from 45 Kb to 929 
Kb (Table 1). Although, assuming recessive inheritance, each 
block qualified as a candidate region, we anticipated from 
consideration of the genomic structure of the Basenji breed 
that the LD block carrying the mutation for the PRA disease 
would be larger than 1 Mb [32]. Furthermore, examination 
of the 0.9 Mb homozygosity interval on CFA13 (39,172,713–
40,101,896) in the CanFam2 genome assembly did not reveal 
any genes appealing as candidates for a retinal degenerative 
disorder.
The four SNPs on CFA25 were all within one 2.09 Mb 
homozygosity block (46,893,645–48,980,899), in which 
all affected dogs were homozygous for one allele for each 
SNP, and the three unaffected dogs were homozygous for 
the complementary allele. One SNP at position 48,147,815 
appeared to break this homozygosity block into two blocks 
of 1.25 Mb and 0.83 Mb, but this was considered unreliable 
as all genotype calls for this SNP were either heterozygous 
or no call (Appendix 3).
Homozygosity analysis: Genotype calls from the affected 
dogs only (n=6) were analyzed for homozygosity blocks 
greater than 1.0 Mb, excluding sex chromosomes. Five 
hundred and thirty-nine such blocks were identified. After 
sorting by chromosome and aligning homozygous regions 
within each chromosome, five loci were identified where all 
Figure 1. Fundus photographs of a nine-year-old Basenji dog affected with progressive retinal atrophy (PRA; Dog 6, Figure 2). A: Fundus 
photographs of the right eye were assembled into a montage. B: Fundus photographs of the left eye were assembled into a montage. Retinal 
degeneration is evidenced by the thin retinal blood vessels (red arrows), pallid optic nerve head (white arrows), and an irregular pattern of 
tapetal reflectivity (yellow arrows). The yellow region immediately superior to the optic nerve head in both eyes (blue arrows) is an expanded 
area of conus (see text).
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six dogs shared a homozygous segment (Table 2): CFA 6, 17, 
21, 25, and 35 with shared block sizes of 2.94, 2.96, 2.73, 1.88, 
and 0.78 Mb, respectively. Haplotype analysis confirmed that 
all six affected dogs were homozygous for the same haplo-
type at each region and reduced the sizes of the homozygous 
blocks to 2.2, 3.1, 2.84, 2.09, and 0.73 Mb, respectively (Table 
2). Two of the three control dogs shared the same genotype as 
the affected dogs in all loci except CFA25. None of the three 
control dogs carried the risk haplotype on CFA25.
Evaluation of candidate genes: From association and homo-
zygosity analyses, the association peak on chromosome 
25 was considered the best potential candidate region to 
investigate further. Within the 2.09 Mb homozygosity block 
encompassing all four SNPs with the maximum p value, two 
genes were evaluated as positional candidates: KCNJ13 and 
SAG. Primer pairs were designed to amplify all exons of both 
genes, including flanking sequences from the 5′ untranslated 
region (UTR), introns, and 3′ UTR (Appendix 2A, B), and 
used to generate amplicons from DNA samples representing 
six dogs: two affected Basenji dogs, three non-affected 
Basenjis, and one normal Boxer dog.
KCNJ13, previously associated with snowflake vitreo-
retinal degeneration and Leber congenital amaurosis in 
humans [30,31], was evaluated with sequence analysis of nine 
amplicons (Appendix 2B) encompassing all three exons. Only 
one polymorphism was identified (exon 2), and was not in 
association with the disease (Appendix 4: A). KCNJ13 was 
not further investigated as a candidate.
SAG, as identified in the Canfam2 genome sequence 
at chr25:47,814,602–47,845,820, comprised 16 exons, 15 
of which are coding. Eighteen amplicons were generated 
encompassing all exons and their flanking 5′ and 3′ UTRs 
and intronic sequence using primers f lanking each exon 
(Appendix 2A), and sequenced. Ten exonic variations were 
identified (Appendix 4B). Two (Nos.1 and 2) were in the 5′ 
UTR in exons 1 and 2, respectively; five (Nos. 3–7) were 
in exonic coding sequence but all represented synonymous 
Figure 2. Pedigree of the six 
Basenji dogs af fected with 
progressive retinal atrophy (PRA) 
selected as cases for the genome-
wide association study. Square 
symbols=males; Circles=females. 
Solid black symbols=affected dogs; 
Grey symbols=dogs of unknown 
phenotype; half-black/half-gray 
symbols=dogs that, assuming auto-
somal recessive inheritance, are at 
least obligate heterozygotes. The 
male dog marked with an asterisk 
is common to the maternal and 
paternal ancestral lines of all six 
affected dogs in this pedigree. Not 
all ancestors or lines of descent are 
shown.
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third-base codon changes and two (No. 9 and 10) were in the 
3′ UTR.
Furthermore, for eight of these ten SAG variations, all 
Basenjis (affected and normal dogs) were homozygous for 
one allele that differed from the allele in the boxer and the 
reference sequence. The two exceptions were variations 8 
and 9, which segregated informatively. Since SNP number 9 
was located in the 3′ UTR of the gene, it seemed unlikely to 
represent a causative mutation.
Variation number 8 (Appendix 4B), however, was a much 
more significant tyrosine to cysteine transition mutation 
at position CFA25:47,845,680 (c.1216T>C; Figure 4) that 
changed the normal stop codon to code for the amino acid 
arginine, which would result in a deduced addition of 25 
amino acids (p.*405Rext*25) to the normal 405 amino acid 
protein (Figure 4), and was thus identified as a strong candi-
date for the causative mutation.
To further evaluate this variation as the candidate muta-
tion, 80 Basenji dogs were then genotyped with PCR amplifi-
cation and sequencing of SAG exon 18 (Table 3). Eighteen of 
these dogs had been diagnosed as phenotypically normal at an 
age considered beyond risk for PRA; 19 had been diagnosed 
Table 1. Peak Genome-wide associaTion ResulTs. 
# Chromosome SNP Base position Size (Mb) of homozygous block observed in affected dogs and location (bp)
1 4 BICF2P1179952 14,140,022 Not observed
2
13







7 BICF2S23222210 42,456,241 0.045 (42,415,530–42,460,613)








Genome-wide association analysis of CanineHD Illumina SNP array data for 6 PRA-affected Basenji dogs and 3 controls, identified 12 
SNPs sharing the highest -log10P-value of 4.6558. The SNP in CFA4 was not within a homozygous block. Seven SNPs in CFA13 were 
within three different homozygous blocks, each smaller than 1 Mb. Four SNPs in CFA25 were within a single 2.09 Mb homozygous 
block.
Figure 3. Manhattan plot presenting 
genome-wide association study 
results in Basenji progressive retinal 
atrophy (PRA). y-axis=Probability 
statistic (–log10(P)) for asso-
ciation test analyzed using PLINK. 
X-Axis=single nucleotide polymor-
phisms ordered on chromosomes 
(chromosomes 39 and 41 represent 
the X-chromosome, and chromo-
some 40 the Y chromosome). 
The highest –log10(P) values are 
observed on CFA4, CFA13, and 
CFA25 as denoted by the black 
arrows.
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as cases affected with PRA, and six were “suspicious for 
PRA” (i.e., tentatively diagnosed clinically as likely to 
develop PRA, based on fundus appearance). Phenotypes for 
the remaining 37 dogs were unassigned, usually because the 
dogs were too young for a confident diagnosis of PRA when 
examined. Among the 18 phenotypically normal Basenjis, 
17 genotyped as either homozygous for the wild-type allele 
at variation number 8 or heterozygous for the presumptive 
mutant allele; the remaining dog (phenotypically normal at 
6.4 years of age) was homozygous for the mutant allele. Given 
the variation in disease onset in some dogs, this finding 
was not unexpected. Of the 19 dogs affected with PRA, 17 
genotyped homozygous for the mutation, and two dogs were 
homozygous for the wild-type allele. In the PRA-suspicious 
group, four dogs were homozygous for the mutant allele, and 
two were heterozygous for the mutation. Of the 37 dogs with 
Table 2. HomozyGosiTy analysis, canineHd illumina snP aRRay daTa in 9 basenji doGs, 6 cases and 3 conTRols.
# CFA Start position End position Size in Mb
Homozygous block location 
(bp) and size (Mb) after haplo-
type analysis
Inclusion of locus 
after comparing to 
controls
1. 6 3,018,918 5,962,902 2.94 3,692,623- 5,896,276 (2.2) No
2. 17 19,570,751 22,531,631 2.96 19,570,699- 22,673,502 (3.1) No
3. 21 5,144,127 7,870,758 2.73 5,095,371- 7,937,895 (2.84) No
4. 25 47,030,007 48,906,876 1.88 46,893,645- 48,980,899 (2.09) Yes
5. 35 14,038,185 14,818,637 0.78 14,091,098- 14,818,637 (0.73) No
Total 5 Loci 11.29 Mb
Five homozygous blocks were identified with sizes between 0.78 and 2.96 Mb. The homozygous block on CFA25 was exclusively present 
in the 6 PRA-affected dogs (cases), all other blocks were observed in both cases and controls.
Figure 4. Sequence of the 3′ end 
of canine S-antigen messenger 
ribonucleic acid and the deduced 
translated protein. Uppercase plain 
letters=coding nucleotide sequence; 
lower case letters=3′ untranslated 
region (UTR); Uppercase bolded 
letters=deduced amino acid trans-
lation; Period (.) indicates Stop 
codon. Bold underlined lowercase 
nucleotides (aataaa)=the polyad-
enylation signal. The sequence ends 
where a poly A tail was observed in 
X98460 messenger RNA (mRNA) 
deposited in the NCBI database. A: 
Sequence from a normal Basenji 
dog is presented. The normal stop 
codon (TGA) is codon 406. A single 
nucleotide polymorphism (SNP) 
(r=A/G) is observed in the 3′ UTR 
of normal dogs as indicated in bold 
italics. B: Sequence from a Basenji 
dog affected with progressive 
retinal atrophy (PRA) is presented. 
The red-boxed nucleotide (C) in panel B is the mutation that alters the normal stop codon (TGA) to code for arginine (R=CGA). Amino 
acids in red are the additional ones introduced by the nonstop mutation.
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no phenotypic assignment, 16 were homozygous for the wild-
type allele, 19 were heterozygous for the mutation, and two 
were homozygous for the mutant allele. An allele-specific 
extension test was conducted on 110 dogs from 22 different 
breeds not known to segregate this disease, and none were 
found to carry this mutation (Appendix 1).
Bronzing phenotype and mutation genotype correlation: 
The SAG mutation in human Oguchi disease is also caus-
ally associated with a discoloration of the fundus, termed the 
Mizuo-Nakamura phenomenon. An altered appearance of the 
tapetal fundus, characterized by a golden-brown discoloration 
and peripheral mottling, is also seen on ophthalmoscopy in 
some Basenji dogs, and termed bronzing. The cases and 
controls in the present association study were deliberately 
chosen from among dogs free of this bronzing phenotype, 
whether affected with PRA or not. To evaluate if this 
bronzing phenomenon might represent a canine homolog of 
the human Mizuo-Nakamura phenomenon, a set of 17 dogs 
diagnosed as exhibiting this bronzing, and 26 dogs free of the 
trait, were genotyped for the canine SAG non-stop mutation. 
No evidence of correlation between the SAG genotype and the 
presence or absence of this bronzing phenotype was observed 
(data not shown).
DISCUSSION
The online Mendelian inheritance in the animal database 
(OMIA) currently lists 614 traits and disorders in dogs, of 
which 238 are Mendelian. For 164 of those, the causative 
mutation is known. More pertinently, 24 mutations have 
currently been reported in 18 genes as causatively associated 
with retinal diseases in at least 58 dog breeds. Approximately 
12 genes result in a PRA phenotype while the rest affect other 
retinal cells or structures [13]. Progress in understanding 
canine population structure, genome history, and the 
opportunities presented by breeds as isolate populations has 
enhanced research by enabling new approaches for mutation 
discovery: from candidate gene approach to linkage studies, 
through linkage disequilibrium, and most recently GWAS. 
The increasing number of trait-causative gene discoveries in 
recent years is testimony to the power of these technologies 
and approaches, especially when combined appropriately 
with canine population structure.
Important criteria in designing an association study 
include accurate phenotypic ascertainment to ensure 
that cases and controls are assigned correctly, and that all 
affected dogs share the same disease; avoidance of strati-
fication between cases and controls to prevent differences 
in population structure between these groups; selection of 
cases that are the least related to each other, to reduce the LD 
interval as much as possible; and analysis of pedigrees for 
evidence supporting inheritance IBD. Since within breeds 
dogs are relatively genetically homogenous, like isolated 
human populations, the number of SNP genotypes sufficient 
for association mapping is estimated to be much lower than 
in diverse human populations, and the number of cases and 
controls could be as low as 20 dogs per group [32]. However, 
the number of dogs required for association mapping is 
also breed dependent, since variation in genomic structure 
is evident between breeds, depending on their origin and 
history, with factors such as bottlenecks impacting haplo-
types and heterogeneity. The Basenji breed, although one of 
the most ancient canine breeds, has low genomic diversity, 
heterozygosity, and number of haplotypes [32]. This is not 
surprising since nearly all the Basenjis in the Western world 
descend from a few dogs originally imported from Africa. 
This suggested that even lower numbers of cases and controls 
than usual might be sufficient for an association study in the 
Basenji compared to other breeds.
In designing the present study, careful selection of cases 
and controls that most stringently met the GWAS criteria 
listed was more critical than the number of cases and controls 
enrolled. In particular, cases were selected that had the most 
clear-cut and consistent disease (stage II disease), and from 
pedigree analysis demonstrated probable IBD recessive 
inheritance; and controls were selected that were free of 
retinal disease at an age likely to be beyond the apparent age 
of risk (at least 6 years of age) and were appropriately related 
to the dogs selected as cases. This reduced the number of 
“high confidence dogs” selected to just six affected dogs and 
three controls.
GWAS initially identified three potentially signifi-
cant loci associated with the disease phenotype, on CFA4, 
CFA13, and CFA25. Haplotype analysis, assuming recessive 





Normal 7 10 1 18
PRA affected 2 0 17 19
PRA suspicious 0 2 4 6
Phenotype is unavailable 16 19 2 37
Total 25 31 24 80
Eighty pedigree-registered Basenji dogs were genotyped for a 
non-stop SAG mutation (c.1216T>C). One phenotypically nor-
mal dog genotyped homozygous for the mutation; 2 dogs di-
agnosed clinically as “PRA affected” genotyped homozygous 
wild-type, and 2 dogs diagnosed clinically as “suspicious of 
having PRA” genotyped heterozygous.
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inheritance, excluded the CFA4 locus. Although homozy-
gosity blocks were observed on CFA13 and CFA25 in affected 
dogs, the LD expected from the Basenji breed structure 
strongly favored CFA25 over CFA13. The success of asso-
ciation mapping combined with homozygosity analysis to 
map the disease to a single locus using fewer than ten dogs 
confirms that the minimum number of dogs needed for 
GWAS is breed dependent, and can be low in breeds where 
LD blocks are large. However, the extensive LD (in this case 
2.09 Mb) presents a potentially frustrating tradeoff. If either 
no obviously appealing candidate genes had been present 
within the homozygosity block, or many were, a much larger 
number of affected dogs would have been needed to reduce 
the LD, the number of potential causative genes, and the 
genomic region to be sequenced and further evaluated.
A parallel approach using homozygosity analysis to 
directly identify candidate regions was also undertaken. 
This method has successfully mapped autosomal recessive 
diseases in humans, especially in consanguineous families. 
Examples include mapping of a severe autosomal recessive 
RP to subsequently identify a causative mutation in MERTK 
[33]; mapping of an autosomal recessive early onset general-
ized dystonia to subsequently identify a causative mutation 
in THAP1 [34]; and homozygosity mapping in one affected 
member of a consanguineous family segregating an autosomal 
recessive RP to identify three candidate regions, totaling 46 
Mb, enabling subsequent identification of the causative muta-
tion in C8orf37 [35]. Because dogs within pedigree-registered 
breeds comprise relatively homogenous closed populations, 
the dogs would be expected to have multiple blocks of homo-
zygosity throughout their genome. That said, if dogs affected 
with an autosomal recessive Mendelian trait are chosen to be 
closely related enough to ensure IBD inheritance, but not so 
closely related that homozygosity segments are excessively 
large or numerous, a homozygosity mapping approach can 
be successful. In the present study, homozygosity analysis 
of six affected dogs genotypes reduced the candidate region 
from the complete genome to just five loci spanning a total 
of 11 Mb.
Subsequent candidate gene evaluation of the CFA25 
interval identified by association and homozygosity mapping 
identified a homozygous non-stop SAG mutation in all six 
dogs affected with PRA in the study set. Non-stop muta-
tions are point mutations that convert the stop codon to code 
for an amino acid, resulting in a deduced elongation of the 
C-terminus of the protein since the translation continues into 
the (normal) 3′ UTR. In one human study, such non-stop 
mutations represented about 0.2% of the codon-changing 
mutations (119 examples in 87 genes) [36]. These mutations 
can potentially affect mRNA fate in terms of stability, local-
ization, translation, and regulation or have ramifications at 
the protein level in terms of stability, localization, folding, 
regulation, and protein–protein interaction. In the mutant 
Basenji SAG sequence, the first alternative in-frame stop 
codon is 72 bases after the mutated stop codon and 37 bp 
upstream from the polyadenylation signal, suggesting that the 
mutated protein, if translated, would be extended by a further 
25 amino acids (Figure 4, Figure 5A-C). This appears to be a 
long enough abnormally extended sequence to support causal 
association with a clinical phenotype [37]. Veske et al. [38] 
previously amplified a full-length cDNA SAG from a normal 
canine retina. Sequence alignment of this cDNA to the canine 
genomic CanFam2.0 and CanFam3.0 sequence assemblies 
identifies GT-AG donor-acceptor sites for all introns, and a 
stop codon at position 1216–1218 in the last coding sequence. 
We amplified full-length canine SAG retinal cDNA that 
yielded the same open reading frame as Veske et al. [38] and 
no other splice variants (data not shown). Moreover, protein 
conservation analysis shows that the stop codon is highly 
conserved (Figure 5D), suggesting the significance of termi-
nation of the C-tail at this position. Either nonsense-mediated 
decay or a protein misfolding response would lead to loss 
of SAG function. Alternatively, if the protein is successfully 
translated, its function would also likely be impaired.
Computational protein analysis of the deduced protein 
(expasy) indicates that the additional 25 amino acids would 
change the isoelectric point to 6.78 (from 6.0 in the wild-type) 
and would add four positively charged residues, for a total of 
56 in the mutant versus 52 in the wild-type. Although the esti-
mated half-life, predicted localization, and instability index 
would not change, it is not certain that the mutant protein 
would fold correctly. If it does, then the mutant protein’s 
ability to bind appropriately to its G-protein-coupled receptor, 
rhodopsin, would likely be impaired, and this would likely 
lead to the retinal degeneration phenotype. SAG (arrestin) is 
critically involved in quenching the photoactivated phosphor-
ylated rhodopsin apoprotein (P-Rh*), a process that involves 
conformational changes in rhodopsin and SAG [39,40]. 
Crystal structure studies have shown that arrestins are elon-
gated two-domain molecules, with their C-tail anchored to 
the body of their N-domain by bulky hydrophobic residues, 
which stabilizes their basal (inactive) conformation [41-44]. 
Receptor binding induces the release of the C-tail and move-
ment of the two domains relative to each other [39,40]. If 
the mutant SAG protein were produced, an elongation of its 
C-tail by 25 amino acids would likely impair its ability to be 
anchored in its N-domain and to respond accurately, appro-
priately and in a timely manner to changes in its receptor.
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Because the SAG gene product serves to turn off acti-
vated rhodopsin during the phototransduction cascade, it may 
be that the “toxic molecule” in SAG associated retinal disease 
is the activated but unquenched opsin apoprotein. This has 
similarly been suggested as the pathogenetic mechanism in 
the T4R opsin mutant dog [45,46] and the T17M opsin mutant 
mouse [47], in both of which light exposure dramatically 
accelerates the rate of retinal degeneration. Similarly, in the 
retinas of SAG knockout mice, photoreceptors are progres-
sively lost when the mice are maintained in cyclic light, 
photoreceptor degeneration was prevented by dark-rearing the 
mice, and the degeneration was markedly accelerated when 
the mice were exposed to constant light [48]. No evidence of 
such light-sensitivity affecting the course of retinal disease 
in Basenjis has yet been adduced, but this issue needs to be 
further evaluated.
In human populations, SAG mutations have previ-
ously been associated with Oguchi disease [10,27,29,49-52] 
and RP [10,11,28]. In some families, different individuals 
Figure 5. Comparative sequence 
analysis, 3′ region of canine 
S-antigen gene. A: This panel 
presents the normal reference 
canine genomic sequence, from 
the CanFam3 canine sequence 
assembly, including the 3’ end of 
intron 15, complete exon 16, and 3′ 
end of S-antigen (SAG). Nucleotides 
comprising the 3′ end of intron 15, 
and the genomic sequence beyond 
the 3′ UTR are in black lowercase. 
The splice acceptor site, ag, at the 5′ 
junction of intron 15 and exon 16 is 
highlighted in red and bolded. Blue 
uppercase characters comprise SAG 
exon 16, the terminal exon, with its 
stop codon TGA highlighted in red 
and bolded. M=C or A, Y=C or T, 
indicate observed canine SNPs. 
Blue lowercase is the 3′ untrans-
lated region (UTR); r1 and r2 are 
A or G SNPs; boxed in gray is the 
deduced stop codon in the affected 
Basenji; bold and underlined is 
the polyadenylation signal. B: The 
corresponding sequence observed 
in unaffected Basenji alleles is 
presented. C: The corresponding 
sequence observed in affected 
Basenji dogs is presented, in which 
the stop codon is mutated to a CGA, 
boxed in red, and the mutation C is 
labeled in red. The resulting extension of the open reading frame is indicated with italics, and the new deduced stop codon TAG is highlighted 
in red. D: Protein conservation analysis of the amino acids translated from the last exon of SAG in six mammalian species. Colors correspond 
to physicochemical properties of the residues: red=small, hydrophobic and/or aromatic; blue=acidic; magenta=basic; green=hydroxyl, sulf-
hydryl, or amine; black dot=stop codon. Conservation symbols indicate: asterisk (*)=positions that have a single, fully conserved residue; 
colon (:)=conservation between groups of strongly similar properties - scoring >0.5 in the Gonnet PAM 250 matrix; period (.)=conservation 
between groups of weakly similar properties - scoring=<0.5 in the Gonnet PAM 250 matrix. Modified from multiple sequence alignment 
generated by Clustal Omega. Nineteen amino acids and the stop codon are highly conserved among human, mouse, rat, horse, cow, and dog.
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homozygous for the same mutation can be affected either by 
Oguchi disease, RP, or both [10,11]. The exact mechanism for 
such a wide range of clinical expression is unknown, although 
variation in light exposure has been proposed as a possible 
modifying factor, based largely on the studies in mouse 
models [48]. We found no significant correlation between 
bronzing of the fundus and the SAG nonstop mutation. This 
suggests that other environmental or genetic factors likely 
are responsible for this bronzing phenomena in the retina 
of Basenji dogs and that the bronzing phenomenon does not 
constitute a risk factor for a Basenji developing this form of 
PRA.
In screening a larger set of 43 ophthalmologically evalu-
ated Basenji dogs in the present study, two dogs diagnosed 
clinically as affected with PRA were identified as homozy-
gous for the SAG wild-type allele; another 6.5-year-old dog 
diagnosed clinically as nonaffected, and initially considered 
to be beyond the risk age, was identified as homozygous for 
the SAG mutant allele; and two dogs that had been diagnosed 
as “suspicious for PRA” at 8 years of age and older were 
genotyped as carriers for the mutation (Table 3). As in other 
breeds [14,53,54], it is likely that more than one PRA-causing 
mutation is segregating in the Basenji breed, and significant 
modifying influences—either genetic or environmental—
also influence the clinical expression of disease caused by 
the primary mutation. Human patients with the same SAG 
mutation as each other can also present a broad spectrum of 
phenotypic expression, and this variation is seen even within 
a single family, with one member affected with the Oguchi 
phenotype and another with RP [11]. Clinical manifestations 
associated with an arrestin 1147delA mutation can range from 
Oguchi disease and Oguchi disease with partial chorioretinal 
degeneration to RP with or without a golden yellow fundus 
reflex [55].
Within the 2.09 Mb LD-homozygous interval identified 
as the disease locus, four refseq genes are located (EIF4E2, 
SAG, UGT1A6, TRPM8) and more than ten non-refseq genes. 
Because the present studies were undertaken in a patient 
population for which only phenotypic data and DNA were 
available, ongoing and future studies in purpose-bred dogs 
will provide tissues, previously and currently unavailable, for 
functional, molecular, transcriptomic, proteomic, and cyto-
logic studies to address critical questions that arise from the 
present investigations, particularly the effect of the non-stop 
mutation on the pathology of the disease, and the involve-
ment of other genes within the LD interval on the course of 
the disease. Basenji dogs affected with PRA can thus serve 
as a novel large animal model of SAG-associated retinal 
degeneration, offering investigational opportunities to better 
understand the primary disease mechanism, explore causes 
for the wide variation of disease as observed in humans and 
Basenji dogs, investigate the effect of the non-stop mutation 
on residual function of the protein, test the potential role 
of light-exposure on the phenotype, and evaluate potential 
therapeutic approaches.
APPENDIX 1. BREEDS AND NUMBER OF DOGS 
PER BREED SCREENED FOR SAG MUTATION.
To access the data, click or select the words “Appendix 1.” A 
total of 110 dogs from 22 different breeds were tested for SAG 
mutation. None of these dogs carry the mutant allele.
APPENDIX 2. PRIMERS USED TO SCREEN 
CANDIDATE GENES WITHIN THE LD INTERVAL 
ON CFA25.
To access the data, click or select the words “Appendix 2.” 
A. Primer information used for SAG screening. B. Primer 
information used for KCNJ13 screening. C. Primer informa-
tion used for the screening of the non-stop mutation in SAG. 
In bold and lower case is the base before the last that was 
altered from the database in C1 and C2 forward primers. In 
red is the mutated base.
APPENDIX 3. GENOTYPE CALLS FOR THE 
SIGNIFICANT LOCUS ON CFA25.
To access the data, click or select the words “Appendix 
3.” Allele are represented as A or B. Colored in green are 
homozygous genotypes for the A allele; Colored in orange 
are homozygous genotypes for the B allele; Colored in yellow 
are the heterozygous genotypes AB. NA=call is not available. 
SNPs within the SAG gene are marked in red. SNPs with 
the highest -log10(P) values are highlighted in purple. The 
homozygous block is boxed. The beginning and end of the 
homozygous block identified by homozygousity analysis are 
bold.
APPENDIX 4. EXONIC POLYMORPHISMS (SNPS) 
IDENTIFIED WITHIN 2 GENES (KCNJ13 AND SAG) 
EVALUATED AS POSITIONAL CANDIDATES FOR 
PROGRESSIVE RETINAL ATROPHY (PRA) IN 
BASENJI DOGS.
To access the data, click or select the words “Appendix 4.” 
All exons from both genes were amplified and sequenced 
from a Boxer, two unaffected Basenjis, one PRA affected 
Basenji and its unaffected sibling. A. Only one exonic SNP 
was identified in KCNJ13; this was not in association with the 
Basenji PRA phenotype. B. Ten exonic SNPs were identified 
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in SAG. Two (Nos.1 and 2) were in the 5′ UTR of exons 1 and 
2, respectively; 5 (Nos. 3–7) were in exonic coding sequence 
but each one was a synonymous third-base codon change; 
and two (Nos. Nine and 10) were in the 3′UTR. SNP No. 
8 (in red), a T>C transition at position 47,845,680 changes 
the normal stop codon to code for arginine, and was thus 
identified as a candidate for the causative mutation. In bold 
are coding sequence SNPs.
ACKNOWLEDGMENTS
Supported by: RO1EY006855, RO1EY17549, R24GM082910; 
The Foundation Fighting Blindness; Van Sloun Fund for 
Canine Genetic Research. Commercial Interests: None. Dr. 
Acland and Dr. Aguirre have an equity interest in and consults 
for Optigen, LLC. Co-corresponding authors: Orly Goldstein 
og26@cornell.edu; Gregory Acland gma2@cornell.edu
REFERENCES
1. Sakmar TP. Structure of rhodopsin and the superfamily of 
seven-helical receptors: the same and not the same.  Curr 
Opin Cell Biol  2002; 14:189-95. [PMID: 11891118].
2. Mendez A, Burns ME, Roca A, Lem J, Wu LW, Simon MI, 
Baylor DA, Chen J. Rapid and reproducible deactivation of 
rhodopsin requires multiple phosphorylation sites.  Neuron 
2000; 28:153-64. [PMID: 11086991].
3. Kühn H, Hall SW, Wilden U. Light-induced binding of 48-KDa 
protein to photoreceptor membranes is highly enhanced by 
phosphorylation of rhodopsin.  FEBS Lett  1984; 176:473-8. 
[PMID: 6436059].
4. Fuchs S, Nakazawa M, Maw M, Tamai M, Oguchi Y, Gal A. 
A homozygous 1-base pair deletion in the arrestin gene is a 
frequent cause of Oguchi disease in Japanese.  Nat Genet 
1995; 10:360-2. [PMID: 7670478].
5. Carr RE, Gouras P. Oguchi’s Disease.  Arch Ophthalmol  1965; 
73:646-56. [PMID: 14281981].
6. Miyake Y, Horiguchi M, Suzuki S, Kondo M, Tanikawa A. 
Electrophysiological findings in patients with Oguchi’s 
disease.  Jpn J Ophthalmol  1996; 40:511-9. [PMID: 9130055].
7. Tanaka K. A case of Oguchi’s disease with retinitis pigmen-
tosa.  Jpn Rev Clin Ophthalmol  1942; 37:1237-.
8. Shimizu S. A family with Oguchi’s disease and with retinitis 
pigmentosa accompanied with glaucoma.  Jpn Rev Clin 
Ophthalmol  1942; 40:218-9. .
9. Yamanaka M. Histologic study of Oguchi’s disease. Its rela-
tionship to pigmentary degeneration of the retina.  Am J 
Ophthalmol  1969; 68:19-26. [PMID: 5306121].
10. Nakamachi Y, Nakamura M, Fujii S, Yamamoto M, Okubo K. 
Oguchi disease with sectoral retinitis pigmentosa harboring 
adenine deletion at position 1147 in the arrestin gene.  Am J 
Ophthalmol  1998; 125:249-51. [PMID: 9467455].
11. Nakazawa M, Wada Y, Tamai M. Arrestin gene mutations in 
autosomal recessive retinitis pigmentosa.  Arch Ophthalmol 
1998; 116:498-501. [PMID: 9565049].
12. Hiroko S, Kei S, Chie I, Yumi T, Hidenao I, Ryuichi I, Masayo 
T, Yozo M. Oguchi disease masked by retinitis pigmentosa. 
Doc Ophthalmol  2011; 123:127-33. [PMID: 21922265].
13. Miyadera K, Acland GM, Aguirre GD. Genetic and phenotypic 
variations of inherited retinal diseases in dogs: the power of 
within- and across-breed studies.  Mamm Genome  2012; 
23:40-61. [PMID: 22065099].
14. Zangerl B, Goldstein O, Philp AR, Lindauer SJ, Pearce-Kelling 
SE, Mullins RF, Graphodatsky AS, Ripoll D, Felix JS, Stone 
EM, Acland GM, Aguirre GD. Identical mutation in a novel 
retinal gene causes progressive rod-cone degeneration in 
dogs and retinitis pigmentosa in humans.  Genomics  2006; 
88:551-63. [PMID: 16938425].
15. Goldstein O, Zangerl B, Pearce-Kelling S, Sidjanin DJ, Kijas 
JW, Felix J, Acland GM, Aguirre GD. Linkage disequilib-
rium mapping in domestic dog breeds narrows the progres-
sive rod-cone degeneration interval and identifies ancestral 
disease-transmitting chromosome.  Genomics  2006; 88:541-
50. [PMID: 16859891].
16. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, 
Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnus-
dottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, 
Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReyn-
olds KM, Bradley KM, Saez B, Godino J, Navarrete 
S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, 
Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Krist-
jansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona 
WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker 
J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar 
T, Stefansson K. Genome-wide association and replica-
tion studies identify four variants associated with prostate 
cancer susceptibility.  Nat Genet  2009; 41:1122-6. [PMID: 
19767754].
17. Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer 
M, de Vries JP, Kranendonk SE, Zeebregts CJ, van Sterken-
burg SM, Geelkerken RH, van Rij AM, Williams MJ, Boll 
AP, Kostic JP, Jonasdottir A, Jonasdottir A, Walters GB, 
Masson G, Sulem P, Saemundsdottir J, Mouy M, Magnusson 
KP, Tromp G, Elmore JR, Sakalihasan N, Limet R, Defraigne 
JO, Ferrell RE, Ronkainen A, Ruigrok YM, Wijmenga C, 
Grobbee DE, Shah SH, Granger CB, Quyyumi AA, Vacca-
rino V, Patel RS, Zafari AM, Levey AI, Austin H, Girelli D, 
Pignatti PF, Olivieri O, Martinelli N, Malerba G, Trabetti 
E, Becker LC, Becker DM, Reilly MP, Rader DJ, Mueller 
T, Dieplinger B, Haltmayer M, Urbonavicius S, Lindblad B, 
Gottsäter A, Gaetani E, Pola R, Wells P, Rodger M, Forgie 
M, Langlois N, Corral J, Vicente V, Fontcuberta J, España 
F, Grarup N, Jørgensen T, Witte DR, Hansen T, Pedersen 
O, Aben KK, de Graaf J, Holewijn S, Folkersen L, Franco-
Cereceda A, Eriksson P, Collier DA, Stefansson H, Stein-
thorsdottir V, Rafnar T, Valdimarsson EM, Magnadottir HB, 
Sveinbjornsdottir S, Olafsson I, Magnusson MK, Palmason 
R, Haraldsdottir V, Andersen K, Onundarson PT, Thor-
geirsson G, Kiemeney LA, Powell JT, Carey DJ, Kuivaniemi 
Molecular Vision 2013; 19:1871-1884 <http://www.molvis.org/molvis/v19/1871> © 2013 Molecular Vision 
1883
H, Lindholt JS, Jones GT, Kong A, Blankensteijn JD, Matthi-
asson SE, Thorsteinsdottir U, Stefansson K. Genome-wide 
association study identifies a sequence variant within the 
DAB2IP gene conferring susceptibility to abdominal aortic 
aneurysm.  Nat Genet  2010; 42:692-7. [PMID: 20622881].
18. Zemunik T, Boban M, Lauc G, Janković S, Rotim K, Vatavuk 
Z, Bencić G, Dogas Z, Boraska V, Torlak V, Susac J, Zobić 
I, Rudan D, Pulanić D, Modun D, Mudnić I, Gunjaca G, 
Budimir D, Hayward C, Vitart V, Wright AF, Campbell H, 
Rudan I. Genome-wide association study of biochemical 
traits in Korcula Island, Croatia.  Croat Med J  2009; 50:23-
33. [PMID: 19260141].
19. Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemp-
pinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, 
Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, 
Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, 
Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, 
Daly MJ, Palotie A, Saarela J, Peltonen L. Genome-wide 
association study in a high-risk isolate for multiple sclerosis 
reveals associated variants in STAT3 gene.  Am J Hum Genet 
2010; 86:285-91. [PMID: 20159113].
20. Liu X, Cheng R, Verbitsky M, Kisselev S, Browne A, Mejia-
Sanatana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford 
B, Frucht S, Fahn S, Marder K, Clark LN, Lee JH. Genome-
wide association study identifies candidate genes for Parkin-
son’s disease in an Ashkenazi Jewish population.  BMC Med 
Genet  2011; 12:104-[PMID: 21812969].
21. Goldstein O, Mezey JG, Boyko AR, Gao C, Wang W, Busta-
mante CD, Anguish LJ, Jordan JA, Pearce-Kelling SE, 
Aguirre GD, Acland GM. An ADAM9 mutation in canine 
cone-rod dystrophy 3 establishes homology with human 
cone-rod dystrophy 9.  Mol Vis  2010; 16:1549-69. [PMID: 
20806078].
22. Tsai KL, Noorai RE, Starr-Moss AN, Quignon P, Rinz CJ, 
Ostrander EA, Steiner JM, Murphy KE, Clark LA. Genome-
wide association studies for multiple diseases of the German 
Shepherd Dog.  Mamm Genome  2012; 23:203-11. [PMID: 
22105877].
23. Seppälä EH, Koskinen LL, Gulløv CH, Jokinen P, Karlskov-
Mortensen P, Bergamasco L, Baranowska Körberg I, 
Cizinauskas S, Oberbauer AM, Berendt M, Fredholm M, 
Lohi H. Identification of a novel idiopathic epilepsy locus in 
Belgian Shepherd dogs.  PLoS ONE  2012; 7:e33549-[PMID: 
22457775].
24. Vernau KM, Runstadler JA, Brown EA, Cameron JM, Huson 
HJ, Higgins RJ, Ackerley C, Sturges BK, Dickinson PJ, 
Puschner B, Giulivi C, Shelton GD, Robinson BH, DiMauro 
S, Bollen AW, Bannasch DL. Genome-wide association 
analysis identifies a mutation in the thiamine transporter 2 
(SLC19A3) gene associated with Alaskan Husky encepha-
lopathy.  PLoS ONE  2013; 8:e57195-[PMID: 23469184].
25. Frischknecht M, Niehof-Oellers H, Jagannathan V, Owczarek-
Lipska M, Drögemüller C, Dietschi E, Dolf G, Tellhelm B, 
Lang J, Tiira K, Lohi H, Leeb TA. COL11A2 mutation in 
Labrador retrievers with mild disproportionate dwarfism. 
PLoS ONE  2013; 8:e60149-[PMID: 23527306].
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, 
Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham 
PC. PLINK: a tool set for whole-genome association and 
population-based linkage analyses.  Am J Hum Genet  2007; 
81:559-75. [PMID: 17701901].
27. Nakamura M, Yamamoto S, Okada M, Ito S, Tano Y, Miyake 
Y. Novel mutations in the arrestin gene and associated 
clinical features in Japanese patients with Oguchi’s disease. 
Ophthalmology  2004; 111:1410-4. [PMID: 15234147].
28. Sonoyama H, Shinoda K, Ishigami C, Tada Y, Ideta H, Ideta R, 
Takahashi M, Miyake Y. Oguchi disease masked by retinitis 
pigmentosa.  Doc Ophthalmol  2011; 123:127-33. [PMID: 
21922265].
29. Sergouniotis PI, Davidson AE, Sehmi K, Webster AR, Robson 
AG, Moore AT. Mizuo-Nakamura phenomenon in Oguchi 
disease due to a homozygous nonsense mutation in the SAG 
gene.  Eye (Lond)  2011; 25:1098-101. [PMID: 21494281].
30. Hejtmancik JF, Jiao X, Li A, Sergeev YV, Ding X, Sharma 
AK, Chan CC, Medina I, Edwards AO. Mutations in KCNJ13 
cause autosomal-dominant snowflake vitreoretinal degenera-
tion.  Am J Hum Genet  2008; 82:174-80. [PMID: 18179896].
31. Sergouniotis PI, Davidson AE, Mackay DS, Li Z, Yang X, 
Plagnol V, Moore AT, Webster AR. Recessive mutations in 
KCNJ13, encoding an inwardly rectifying potassium channel 
subunit, cause leber congenital amaurosis.  Am J Hum Genet 
2011; 89:183-90. [PMID: 21763485].
32. Vonholdt BM, Pollinger JP, Lohmueller KE, Han E, Parker 
HG, Quignon P, Degenhardt JD, Boyko AR, Earl DA, Auton 
A, Reynolds A, Bryc K, Brisbin A, Knowles JC, Mosher DS, 
Spady TC, Elkahloun A, Geffen E, Pilot M, Jedrzejewski 
W, Greco C, Randi E, Bannasch D, Wilton A, Shearman J, 
Musiani M, Cargill M, Jones PG, Qian Z, Huang W, Ding 
ZL, Zhang YP, Bustamante CD, Ostrander EA, Novembre 
J, Wayne RK. Genome-wide SNP and haplotype analyses 
reveal a rich history underlying dog domestication.  Nature 
2010; 464:898-902. [PMID: 20237475].
33. Ksantini M, Lafont E, Bocquet B, Meunier I, Hamel CP. 
Homozygous mutation in MERTK causes severe autosomal 
recessive retinitis pigmentosa.  Eur J Ophthalmol  2012; 
22:647-53. [PMID: 22180149].
34. Schneider SA, Ramirez A, Shafiee K, Kaiser FJ, Erogullari A, 
Brüggemann N, Winkler S, Bahman I, Osmanovic A, Shafa 
MA, Bhatia KP, Najmabadi H, Klein C, Lohmann K. Homo-
zygous THAP1 mutations as cause of early-onset generalized 
dystonia.  Mov Disord  2011; 26:858-61. [PMID: 21425335].
35. Estrada-Cuzcano A, Neveling K, Kohl S, Banin E, Rotenst-
reich Y, Sharon D, Falik-Zaccai TC, Hipp S, Roepman R, 
Wissinger B, Letteboer SJ, Mans DA, Blokland EA, Kwint 
MP, Gijsen SJ, van Huet RA, Collin RW, Scheffer H, Veltman 
JA, Zrenner E. European Retinal Disease Consortium.  den 
Hollander AI, Klevering BJ, Cremers FP. Mutations in 
C8orf37, encoding a ciliary protein, are associated with 
autosomal-recessive retinal dystrophies with early macular 
involvement.  Am J Hum Genet  2012; 90:102-9. [PMID: 
22177090].
Molecular Vision 2013; 19:1871-1884 <http://www.molvis.org/molvis/v19/1871> © 2013 Molecular Vision 
1884
36. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas 
NS, Cooper DN. The Human Gene Mutation Database: 2008 
update.  Genome Med.  2009; 1:13-[PMID: 19348700].
37. Hamby SE, Thomas NST, Cooper DN, Chuzhanova N. A meta-
analysis of single base-pair substitutions in translational 
termination codons (‘nonstop’ mutations) that cause human 
inherited disease.  Hum Genomics  2011; 5:241-64. [PMID: 
21712188].
38. Veske A, Narfström K, Finckh U, Sargan DR, Nilsson SE, Gal 
A. Isolation of canine retinal arrestin cDNA and exclusion of 
three candidate genes for Swedish Briard retinal dystrophy. 
Curr Eye Res  1997; 16:270-4. [PMID: 9088745].
39. Kirchberg K, Kim TY, Möller M, Skegro D, Dasara Raju G, 
Granzin J, Büldt G, Schlesinger R, Alexiev U. Conforma-
tional dynamics of helix 8 in the GPCR rhodopsin controls 
arrestin activation in the desensitization process.  Proc Natl 
Acad Sci USA  2011; 108:18690-5. [PMID: 22039220].
40. Gurevich VV, Gurevich EV. Custom-designed proteins as 
novel therapeutic tools? The case of arrestins.  Expert Rev 
Mol Med  2010; 12:e13-[PMID: 20412604].
41. Hirsch JA, Schubert C, Gurevich VV, Sigler PB. The 2.8 A 
crystal structure of visual arrestin: a model for arrestin’s 
regulation.  Cell  1999; 97:257-69. [PMID: 10219246].
42. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert 
C. Crystal structure of beta-arrestin at 1.9 A: possible 
mechanism of receptor binding and membrane Translocation. 
Structure  2001; 9:869-80. [PMID: 11566136].
43. Milano SK, Pace HC, Kim YM, Brenner C, Benovic JL. Scaf-
folding functions of arrestin-2 revealed by crystal structure 
and mutagenesis.  Biochemistry  2002; 41:3321-8. [PMID: 
11876640].
44. Sutton RB, Vishnivetskiy SA, Robert J, Hanson SM, Raman D, 
Knox BE, Kono M, Navarro J, Gurevich VV. Crystal struc-
ture of cone arrestin at 2.3A: evolution of receptor specificity. 
J Mol Biol  2005; 354:1069-80. [PMID: 16289201].
45. Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling 
SE, Sumaroka A, Acland GM, Aguirre GD. In vivo dynamics 
of retinal injury and repair in the rhodopsin mutant dog 
model of human retinitis pigmentosa.  Proc Natl Acad Sci 
USA  2005; 102:5233-8. [PMID: 15784735].
46. Zhu L, Jang GF, Jastrzebska B, Filipek S, Pearce-Kelling 
SE, Aguirre GD, Stenkamp RE, Acland GM, Palczewski 
K. Naturally occurring mutation of the opsin gene (T4R) 
in dogs affects glycosylation and stability of the G protein-
coupled receptor.  J Biol Chem  2004; 279:53828-39. [PMID: 
15459196].
47. White DA, Fritz JJ, Hauswirth WW, Kaushal S, Lewin AS. 
Increased sensitivity to light-induced damage in a mouse 
model of autosomal dominant retinal disease.  Invest 
Ophthalmol Vis Sci  2007; 48:1942-51. [PMID: 17460245].
48. Chen J, Simon MI, Matthes MT, Yasumura D, LaVail MM. 
Increased susceptibility to light damage in an arrestin 
knockout mouse model of Oguchi disease (stationary night 
blindness).  Invest Ophthalmol Vis Sci  1999; 40:2978-82. 
[PMID: 10549660].
49. Saga M, Mashima Y, Kudoh J, Oguchi Y, Shimizu N. Gene 
analysis and evaluation of the single founder effect in Japa-
nese patients with Oguchi disease.  Jpn J Ophthalmol  2004; 
48:350-2. [PMID: 15295660].
50. Maw M, Kumaramanickavel G, Kar B, John S, Bridges R, 
Denton M. Two Indian siblings with Oguchi disease are 
homozygous for an arrestin mutation encoding premature 
termination.  Hum Mutat  1998; Suppl 1S317-9. [PMID: 
9452120].
51. Waheed NK, Qavi AH, Malik SN, Maria M, Riaz M, Cremers 
FP, Azam M, Qamar R. A nonsense mutation in S-antigen 
(p.Glu306*) causes Oguchi disease.  Mol Vis  2012; 18:1253-9. 
[PMID: 22665972].
52. Huang L, Li W, Tang W, Zhu X, Ou-Yang P, Lu G. A Chinese 
family with Oguchi’s disease due to compound heterozy-
gosity including a novel deletion in the arrestin gene.  Mol 
Vis  2012; 18:528-36. [PMID: 22419846].
53. Goldstein O, Guyon R, Kukekova A, Kuznetsova TN, Pearce-
Kelling SE, Johnson J, Aguirre GD, Acland GM. COL9A2 
and COL9A3 mutations in canine autosomal recessive 
oculoskeletal dysplasia.  Mamm Genome  2010; 21:398-408. 
[PMID: 20686772].
54. Downs LM, Wallin-Håkansson B, Boursnell M, Marklund 
S, Hedhammar Å, Truvé K, Hübinette L, Lindblad-Toh K, 
Bergström T, Mellersh CS. A frameshift mutation in golden 
retriever dogs with progressive retinal atrophy endorses 
SLC4A3 as a candidate gene for human retinal degenera-
tions.  PLoS ONE  2011; 6:e21452-[PMID: 21738669].
55. Nakazawa M, Wada Y, Fuchs S, Gal A, Tamai M. Oguchi 
disease: phenotypic characteristics of patients with the 
frequent 1147delA mutation in the arrestin gene.  Retina 
1997; 17:17-22. [PMID: 9051837].
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. 
The print version of this article was created on 27 August 2013. This reflects all typographical corrections and errata to the 
article through that date. Details of any changes may be found in the online version of the article.
